3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
19
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Neoplasms
9
Carcinoma, Non-Small-Cell Lung
7
Colorectal Neoplasms
6
Breast Neoplasms
6
Prostatic Neoplasms
5
Papillomavirus Infections
5
Ovarian Neoplasms
4
Neoplastic Cells, Circulating
4
Uterine Cervical Neoplasms
3
Uterine Cervical Dysplasia
3
Lung Neoplasms
3
Melanoma
2
Lymphoma, Follicular
2
Leukemia, Myeloid, Acute
2
Hematologic Neoplasms
2
Carcinoma, Hepatocellular
2
Thymic aplasia
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Small Cell Lung Carcinoma
1
Respiratory Distress Syndrome
1
Recurrence
1
Rectal Neoplasms
1
Radiation Injuries
1
Pulmonary Disease, Chronic Obstructive
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Pancreatic Neoplasms
1
Osteosarcoma
1
Opioid-Related Disorders
1
Interventions
Bevacizumab
27
Leucovorin
23
Fluorouracil
22
Oxaliplatin
17
Irinotecan
15
Cetuximab
14
pembrolizumab
11
IFL protocol
11
Panitumumab
10
Folfox protocol
10
Capecitabine
10
Gemcitabine
7
adagrasib
5
Cisplatin
5
Carboplatin
5
Ramucirumab
4
Colonoscopy
4
veliparib
3
spartalizumab
3
selpercatinib
3
regorafenib
3
labetuzumab
3
durvalumab
3
conatumumab
3
cemiplimab
3
Pemetrexed
3
Paclitaxel
3
HMPL-013
3
Drug Therapy
3
5,11-methenyltetrahydrohomofolate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Colonic Neoplasms
×
Blood Specimen Collection
×
Clear all
NCT06703632
2025-02-27
MS-Prevecol
ADVANCED MARKER DISCOVERY S.L.
Phase NA
Recruiting
4,538 enrolled